Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GDRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDRXGoodRx$2.65+3.5%$2.30$1.77▼$5.81$907.82M1.541.72 million shs1.18 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDRXGoodRx0.00%+9.05%+15.22%+7.29%-30.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDRXGoodRx$2.65+3.5%$2.30$1.77▼$5.81$907.82M1.541.72 million shs1.18 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDRXGoodRx0.00%+9.05%+15.22%+7.29%-30.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGDRXGoodRx 2.13Hold$3.8143.87% UpsideCurrent Analyst Ratings BreakdownLatest GDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026GDRXGoodRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/14/2026GDRXGoodRx CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.005/11/2026GDRXGoodRx TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.005/8/2026GDRXGoodRx The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.505/6/2026GDRXGoodRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/10/2026GDRXGoodRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/4/2026GDRXGoodRx Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$7.00 ➝ $3.503/3/2026GDRXGoodRx CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.50 ➝ $3.503/2/2026GDRXGoodRx The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.00 ➝ $2.502/27/2026GDRXGoodRx MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.00 ➝ $3.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGDRXGoodRx$787.89M1.15$0.40 per share6.62$1.82 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGDRXGoodRx$30.44M$0.0644.1713.251.692.61%7.90%3.23%8/5/2026 (Estimated)Latest GDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026GDRXGoodRx$0.07$0.07N/AN/A$185.40 million$194.01 million2/25/2026Q4 2025GDRXGoodRx$0.09$0.09N/A$0.02$193.27 million$194.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGDRXGoodRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGDRXGoodRx0.781.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGDRXGoodRx63.77%Insider OwnershipCompanyInsider OwnershipGDRXGoodRx5.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGDRXGoodRx950342.57 million322.47 millionOptionableGDRX HeadlinesRecent News About These CompaniesGoldman Sachs Keeps Their Hold Rating on GoodRx Holdings (GDRX)May 21 at 6:26 PM | theglobeandmail.comGoodRx: Evident Stabilization, But GLP-1 Dependence Is A Risk (Upgrade)May 21 at 8:24 AM | seekingalpha.comGoodRx Earnings Call Highlights Pharma Direct MomentumMay 19, 2026 | theglobeandmail.comJim Cramer on GoodRx: “I’m Going to Grant You That Spec”May 15, 2026 | finance.yahoo.comGoodRx Holdings (GDRX) price target increased by 10.24% to 3.17May 15, 2026 | msn.comGoodRx Holdings' (NASDAQ:GDRX) Soft Earnings Are Actually Better Than They AppearMay 15, 2026 | finance.yahoo.comThe 5 most interesting analyst questions from GoodRx’s Q1 earnings callMay 14, 2026 | msn.comGoodRx (GDRX) Q1 2026 Earnings Call TranscriptMay 9, 2026 | finance.yahoo.comGoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comGoodRx (GDRX) stock trades up, here is whyMay 7, 2026 | msn.comGoodRx Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comBig Pharma Runs Its Checkout Counter Through GoodRxMay 7, 2026 | pymnts.comShould You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?May 7, 2026 | zacks.comGoodRx (NASDAQ:GDRX) Issues Earnings ResultsMay 6, 2026 | marketbeat.comGoodRx (NASDAQ:GDRX) Beats Q1 CY2026 Sales ExpectationsMay 6, 2026 | finance.yahoo.comGoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 6, 2026 | zacks.comGoodRx Holdings, Inc. (GDRX) Q1 Earnings Match EstimatesMay 6, 2026 | zacks.comGoodRx Reports First Quarter 2026 ResultsMay 6, 2026 | businesswire.comGoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of "Hold" from BrokeragesMay 6, 2026 | marketbeat.comGoodRx (NASDAQ:GDRX) Trading 8.7% Higher - Should You Buy?May 1, 2026 | marketbeat.comGoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes PatientsMay 1, 2026 | businesswire.comMedia Sentiment Over TimeGDRX Company DescriptionsGoodRx NASDAQ:GDRX$2.65 +0.09 (+3.52%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.66 +0.00 (+0.19%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
